News Avalyn seeks $300m from its IPO Pulmonary fibrosis drug developer Avalyn prices its IPO at around $300m, as Seaport and Hemab both target $180m-plus from their listings.
News Ray's upscaled Series B, and other biofinancings This week's crop of private financings includes nine-figure rounds for Ray Therapeutics and Tortugas, with Serif and Alloy also in on the action.
News Lift for UK healthtech as fund bags £100m from national bank A new Apposite Capital fund has been set up with £100m to provide much-needed scale-up funding for UK biopharma and healthtech companies.
News Beeline raises $300m for BMS drugs, and other biofinancings Beeline Medicines, Oricell, Terremoto, Harbinger, Neomorph, Adcendo, and STORM all closed impressive financing rounds in the last week.
News Pulmonary fibrosis drug developer Avalyn files IPO Avalyn Pharma hops on the IPO train, filing to list on the Nasdaq and raise funds for late-stage trials of its inhaled pulmonary fibrosis therapies.
News Syneron raises $150m for macrocyclics, and other financings Our round-up of recent biotech venture capital financings includes nine-figure rounds for Syneron, Stipple Bio, and Sidewinder.
News Parexel buys Vitrana to boost patient safety toolkit Contract research organisation Parexel has bought Vitrana and its AI-powered pharmacovigilance platform for an undisclosed sum.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
